Recon: FDA approves J&J’s, Legend’s Carvykti for treating second-line multiple myeloma; FDA rejects Supernus’ Parkinson’s disease combo yet again
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States